Part II: New candidates of pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors

• Published in: European journal of medicinal chemistry Vol. 144; pp. 859 - 873
• Main Authors: Galal, Shadia A., Khairat, Sarah H.M., Ali, Hamed I., Shouman, Samia A., Attia, Yasmin M., Ali, Mamdouh M., Mahmoud, Abeer E., Abdel-Halim, Abeer H., Fyiad, Amal A., Tabll, Ashraf, El-Shenawy, Reem, El Abd, Yasmine S., Ramdan, Raghda, El Diwani, Hoda I.
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 20-01-2018
• Subjects: 2-Arylbenzimidazoles; Cell cycle; Chk2 inhibitors; Genotoxic anticancer therapies; Pyrazoles; Genotoxic anticancer therapies; 2-Arylbenzimidazoles; Pyrazoles; Chk2 inhibitors; Cell cycle
• ISSN: 0223-5234; 1768-3254
• DOI: 10.1016/j.ejmech.2017.12.023

The development of checkpoint kinase 2 (Chk2) inhibitors for the treatment of cancer has been an ongoing and attractive objective in drug discovery. In this study, twenty-one feasible pyrazole-benzimidazole conjugates were synthesized to study their effect against Chk2 activity using Checkpoint Kinase Assay. The antitumor activity of these compounds was investigated using SRB assay. A potentiation effect of the synthesized Chk2 inhibitors was also investigated using the genotoxic anticancer drugs cisplatin and doxorubicin on breast carcinoma, (ER+) cell line (MCF-7). In vivo Chk2 and antitumor activities of 8d as a single-agent, and in combination with doxorubicin, were evaluated in breast cancer bearing animals induced by N-methylnitrosourea. The effect of 8d alone and in combination with doxorubicin was also studied on cell-cycle phases of MCF-7 cells using flow cytometry analysis. The results revealed their potencies as Chk2 inhibitors with IC50 ranges from 9.95 to 65.07 nM. Generally the effect of cisplatin or doxorubicin was potentiated by the effect of most of the compounds that were studied. The in vivo results indicated that the combination of 8d and doxorubicin inhibited checkpoint kinase activity more than either doxorubicin or 8d alone. There was a positive correlation between checkpoint kinase inhibition and the improvement observed in histopathological features. Single dose treatment with doxorubicin or 8d produced S phase cell cycle arrest whereas their combination created cell cycle arrest at G2/M from 8% in case of doxorubicin to 51% in combination. Gold molecular modelling studies displayed a high correlation to the biological results.
[Display omitted]
•The synthesized compounds inhibited Chk2 activity with high potency.•They have chemotherapeutic potential.•Combined treatment of 8b and doxorubicin induced the cell cycle arrest.•In vivo Chk2 and antitumor activities were investigated.